

Supplementary Table 2. Proportion of Patients With Clinical Remission (CDAI <150) and Normalization of High-sensitivity-CRP (hs-CRP <3 mg/L), or Clinical Remission and 50% Reduction of hs-CRP During the Double-blind Phase (Nonresponder Imputation Analysis)

| Wk | CDAI <150 and hs-CRP <3 mg/L | | CDAI <150 and 50% reduction in hs-CRP | |
|----|---------------------------------|----------------------|--|----------------------|
| | ADA 80/40 mg (n=15) | ADA 160/80 mg (n=15) | ADA 80/40 mg (n=15) | ADA 160/80 mg (n=15) |
| 2 | 2 (13.3) | 2 (13.3) | 3 (20.0) | 7 (46.7) |
| 4 | 2 (13.3) | 6 (33.3) | 3 (20.0) | 8 (53.3) |
| 6 | 4 (26.7) | 5 (33.3) | 6 (40.0) | 9 (60.0) |
| 8 | 4 (26.7) | 5 (33.3) | 6 (40.0) | 6 (40.0) |

Values are presented as n (%).

ADA, adalimumab.